Étiquette : trouble mental

Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case, Cornel N. Stanciu and Thomas M. Penders, 2016.

Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case Cornel N. Stanciu and Thomas M. Penders Current Psychiatry Reviews, 2016, Vol. 12, No. 2, 1-3. DOI: 10.2174/1573400512666160216234850   Abstract : Hallucinogen Persistent Perception Disorder (HPPD) is considered an “uncommon” disorder described in association with use of hallucinogens such as LSD, mescaline and psilocybin. Despite multiple mentions of persistence of visual disturbances reported by users on online forums, clinicians may not be aware of this complication. There have been few descriptions of HPPD in association with use of new psychoactive substances (such as 2C-E). Increasing use of these designer stimulants places [...]

Lire la suite

The Role of MDMA Neurotoxicity in Anxiety, Casey R. Guillot et al., 2007

The Role of MDMA Neurotoxicity in Anxiety Casey R. Guillot, Mitchell E. Berman and Brenton R. Abadie In : Neurotoxicity Syndromes, Chapter I ISBN: 978-1-60021-797-5 Editor: Linda R. Webster, pp. 1 - 36 © 2007 Nova Science Publishers, Inc. Abstract The drug 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) long has been considered a neurotoxin selective for serotonin (5-hydroxytryptamine; 5-HT) axons in rats and nonhuman primates. MDMA is also thought to have the potential to cause persistent serotonergic alterations in humans. Since the serotonin system is involved in the regulation of anxiety, researchers have proposed that recreational Ecstasy users may be at risk for the development of anxiety disorders and symptoms. [...]

Lire la suite

Heavy cannabis use, dependence and the brain : a clinical perspective, Emese Kroon et al., 2019

Heavy cannabis use, dependence and the brain : a clinical perspective Emese Kroon, Lauren Kuhns, Eva Hoch & Janna Cousijn Addictions, 2019, 1-12. doi : 10.1111/add.14776   ABSTRACT Aims : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, cannabis use disorder (CUD) and the brain. Methods : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. Results : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]

Lire la suite

Switch to mania after ayahuasca consumption in a man with bipolar disorder : a case report, Alejandro G Szmulewicz et al., 2015

Switch to mania after ayahuasca consumption in a man with bipolar disorder : a case report Alejandro G Szmulewicz, Marina P Valerio and Jose M Smith International Journal of Bipolar Disorders, 2015, 3, (4), 1-3. DOI 10.1186/s40345-014-0020-y   Abstract Background : There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing evidence for the antidepressant properties of its components. However, there are no reports on the effects of this substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor. Case report : We present the case of [...]

Lire la suite

The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study, Nadav Shalita et al., 2019

The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]

Lire la suite

Heavy Cannabis Use, Dependence and the Brain : A Clinical Perspective, KROON E. et al., 2019

Heavy Cannabis Use, Dependence and the Brain: A Clinical Perspective KROON E., KUHNS L., HOCH E., COUSIJN J. Addictions,  2019 Aug 13. doi: 10.1111/add.14776. PMID: 31408248 Abstract AIMS : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, Cannabis Use Disorder (CUD), and the brain. METHODS : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. RESULTS : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]

Lire la suite

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies, Matthew E. Sloan et al., 2018

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies Matthew E. Sloan, Caroline W. Grant, Joshua L. Gowin, Vijay A. Ramchandani and Bernard Le Foll Acta Pharmacologica Sinica, 2018, 0, 1–9; https://doi.org/10.1038/s41401-018-0081-z   Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric [...]

Lire la suite

Reefer Madness : A Case of Cannabis-Induced Psychosis, Matthew C. Ballenberger et al., 2019

Reefer Madness : A Case of Cannabis-Induced Psychosis Matthew C. Ballenberger,  Robert D. Glatter,  Daniel P. Klein,  Steven Mandel, Medscape Psychiatry,  August 15, 2019 Clinical Presentation A 32-year-old woman with a history of iron-deficiency anemia was brought in by ambulance because of altered mental status. The patient's sister and boyfriend reported that 1 day before presentation, the patient had ingested a marijuana edible and a few hours later developed fatigue and nausea, followed by at least 15 episodes of nonbloody, nonbilious, projectile vomiting throughout the night. In the morning, she became very pale, her lips turned blue, and she became stiff, losing consciousness for [...]

Lire la suite

Lysergic Acid Diethylamide and Psilocybin Revisited, Mark A. Geyer, 2015

Lysergic Acid Diethylamide and Psilocybin Revisited Mark A. Geyer Biological Psychiatry, 2015, Volume 78, Issue 8, 544-553 https://doi.org/10.1016/j.biopsych.2015.08.003   The past decade brought the beginnings of a renaissance in research on psychedelic drugs. Two articles in this issue of Biological Psychiatry signify that the resurrection of this long ignored topic has begun to mature and bear at least the promise of fruit. In the early 1970s, the onset of the “War on Drugs” brought with it a near-total hiatus in serious research on psychedelic drugs, especially in the United States. The resumption of credible work in this area has come from Switzerland, where many of [...]

Lire la suite

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction, Nicolas A. Bercelet al., 1956

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction Nicolas A. Bercel, Lee E. Travis, Leonard B. Olinger & E. Dreikurs AMA Archives of Neurology and Psychiatry, 1956, 588-611 republishing :Psychopathology: A Source Book (pp. 605–639). DOI: https://doi.org/10.4159/harvard.9780674367012 Keywords : Cardiovascular Agents, Ergot Alkaloids, adverse effects, Lysergic Acid Diethylamide, Mental Disorders, Oxytocics, Paranoid Disorders, Psychotic Disorders INTRODUCTION Experimental psychosis has a long history. It might have started with the administration of Cannabis indica boiling in wine to the ancient Hun warriors, resulting in mental obfuscation, as they were prepared for surgery because of wounds sustained in battle. [...]

Lire la suite